These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 18330028)
21. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment. Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970 [TBL] [Abstract][Full Text] [Related]
22. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Henry DH; Abels RI Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722 [TBL] [Abstract][Full Text] [Related]
23. The use of erythropoiesis-stimulating agents in the intensive care unit. Piagnerelli M; Vincent JL Crit Care Clin; 2012 Jul; 28(3):345-62, v. PubMed ID: 22713610 [TBL] [Abstract][Full Text] [Related]
24. Erythropoietin-stimulating agents: new data yield new insights. Zitella L Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):36-8. PubMed ID: 18154208 [No Abstract] [Full Text] [Related]
25. Is anemia of cancer different from chemotherapy-induced anemia? Steensma DP J Clin Oncol; 2008 Mar; 26(7):1022-4. PubMed ID: 18227523 [No Abstract] [Full Text] [Related]
26. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia. Bohlius J; Engert A; Schwarzer G JAMA; 2008 Dec; 300(24):2854-5; author reply 2855-7. PubMed ID: 19109112 [No Abstract] [Full Text] [Related]
27. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Schwartz RN Am J Health Syst Pharm; 2007 Feb; 64(3 Suppl 2):S5-13; quiz S28-30. PubMed ID: 17244886 [TBL] [Abstract][Full Text] [Related]
28. [Use of erythropoietin in the treatment of cancer-related anemia]. Huang JX; Meng FJ Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):877-8. PubMed ID: 22335959 [No Abstract] [Full Text] [Related]
29. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia". Coiffier B Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359 [No Abstract] [Full Text] [Related]
30. Erythropoiesis-stimulating agents for the management of anemia of chronic kidney disease: past advancements and current innovations. Dutka P Nephrol Nurs J; 2012; 39(6):447-57. PubMed ID: 23469411 [TBL] [Abstract][Full Text] [Related]
31. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin. Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG Biochim Biophys Acta; 2007 Sep; 1776(1):1-9. PubMed ID: 17683868 [TBL] [Abstract][Full Text] [Related]
33. Use of agents stimulating erythropoiesis in digestive diseases. Moreno López R; Sicilia Aladrén B; Gomollón García F World J Gastroenterol; 2009 Oct; 15(37):4675-85. PubMed ID: 19787831 [TBL] [Abstract][Full Text] [Related]
35. Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor? Tefferi A Mayo Clin Proc; 2007 Nov; 82(11):1316-8. PubMed ID: 17976350 [No Abstract] [Full Text] [Related]
36. The effects of anemia and anemia treatment on the quality of life of people with cancer. Cella D Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):125-32. PubMed ID: 12380962 [TBL] [Abstract][Full Text] [Related]
37. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Abdel-Razeq H; Hashem H Crit Rev Oncol Hematol; 2020 Jan; 145():102837. PubMed ID: 31830663 [TBL] [Abstract][Full Text] [Related]
38. Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies? Gupta G; Choi MJ Semin Dial; 2011; 24(4):379-81. PubMed ID: 21801225 [No Abstract] [Full Text] [Related]